MiniMed 780G System Receives Health Canada License
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Should l Buy MMED?
Source: Newsfilter
- Software Approval: MiniMedGroup, Inc. announced that its MiniMed™ 780G system has received new software licensing from Health Canada, marking a significant advancement in diabetes care that is expected to enhance treatment experiences for Canadian patients.
- Technological Innovation: The new system integrates Meal Detection™ technology and SmartGuard™, compatible with both Guardian™ 4 and Simplera Sync™ sensors, allowing users to manage glucose levels more flexibly, particularly for adults aged 18 and older with Type 2 diabetes.
- Clinical Effectiveness: The MiniMed™ 780G system has demonstrated over 80% time in range in clinical and real-world applications globally, significantly exceeding the international target of 70%, indicating its effectiveness in diabetes management.
- Enhanced User Experience: The introduction of the Simplera Sync™ sensor will reduce daily injection frequency, providing a more comfortable wearing experience, which is expected to further alleviate the daily management burden for patients and strengthen MiniMed's leadership position in the diabetes treatment market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MMED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MMED
Wall Street analysts forecast MMED stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 11.730
Low
Averages
High
Current: 11.730
Low
Averages
High
About MMED
MiniMed Group, Inc. is a medical technology company, which develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Its fully integrated system addresses pain points for people with diabetes (PWD): health outcomes and complexity of diabetes management. The MiniMed 780G is its flagship AID system. The MiniMed 780G system uses its SmartGuard dosing algorithm technology, which automatically delivers basal insulin and auto-correction doses every five minutes based on sensor glucose readings. The MiniMed 780G consists of the MiniMed 780G insulin pump, the Simplera Sync CGM sensor, and the instinct sensor. Its platform of clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and a Smart Multiple Daily Injection (MDI) System. Its pipeline products are the MiniMed Flex, screenless insulin pump, next-generation Vivera dosing algorithm, and MiniMed Fit patch pump with extended wear.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Long-Term Investment Opportunities Amid Market Uncertainty
- UPS's Transformation Progress: Despite challenges from Amazon's open delivery network, UPS is shifting towards higher-margin customers, achieving revenue per package growth, and is expected to reach a business inflection point in the second half of 2026, indicating strong long-term investment potential.
- Hormel's Brand Revamp: After a 60% drop in stock price, Hormel Foods is reworking its brand and product portfolio, with recent organic growth trending upward, and its 5.6% dividend yield providing stable returns for long-term investors, showcasing resilience during tough times.
- Medtronic's Focus Strategy: Medtronic is enhancing profitability by spinning off its diabetes business and launching new products like the Hugo surgical robot; despite a 40% stock price decline, its 3.6% dividend yield remains attractive to long-term investors, underscoring its leadership in the medical device sector.
- Importance of Dividends: UPS, Hormel, and Medtronic all offer stable dividends, helping investors maintain confidence during market volatility, and while the market may not fully recognize these companies' business improvements, their long-term outlook remains optimistic.
See More
Long-Term Investment Potential of UPS, Hormel, and Medtronic
- UPS Transformation Progress: Despite competition from Amazon, UPS is shifting towards higher-margin customers and expects to achieve a business turnaround by the second half of 2026, with revenue per package growth indicating management's successful strategy, while a 6.5% dividend yield attracts long-term investors.
- Hormel Brand Restructuring: Hormel Foods is reworking its brand and product portfolio after a 60% stock price decline, with recent organic growth trends improving; its 5.6% dividend yield and 46% controlling stake provide flexibility for long-term decision-making.
- Medtronic Profitability Focus: Medtronic is enhancing profitability by spinning off its diabetes business, which is expected to positively impact earnings; despite a 40% decline from its 2021 high, its 3.6% dividend yield remains appealing to long-term investors.
- Importance of Dividends: UPS, Hormel, and Medtronic offer stable dividends in an uncertain market, helping investors maintain confidence during volatility, while also making significant progress in their business overhauls.
See More
Medtronic Shares Decline, Investors Should Take Note
- Stock Decline: Medtronic (MDT) shares have fallen 40% from their 2021 peak, currently priced at $76.03, reflecting market pessimism about its future performance, prompting investors to assess risks carefully.
- Business Restructuring: The company is readjusting its product portfolio to focus on higher-margin businesses, planning to spin off its lower-margin diabetes division, MiniMed, which is expected to enhance overall profit margins and positively impact earnings.
- New Product Launch: Medtronic is introducing the Hugo surgical robot to fill a market gap, leveraging its strong customer relationships in the healthcare sector, which is anticipated to receive a positive market response and drive future growth.
- Dividend Yield: With a dividend yield of 3.73% and a history of 48 consecutive years of dividend increases, Medtronic, despite recent modest hikes, is positioned for potential faster dividend growth in the future, attracting long-term investor interest.
See More
Medtronic Faces Challenges but Holds Great Potential
- Stock Price Decline: Medtronic's shares have fallen 40% from their 2021 peak, reflecting market concerns over its profitability and growth outlook, although the current dividend yield of 3.6% offers an attractive proposition for investors.
- Portfolio Restructuring: The company is readjusting its product portfolio to focus on higher-margin businesses, planning to spin off its lower-margin diabetes division, MiniMed, which is expected to enhance overall margins and immediately boost earnings.
- New Product Launch: Medtronic is introducing the Hugo surgical robot, which is anticipated to be well-received in the market, especially given its strong customer relationships in the healthcare sector, aiding future growth prospects.
- Dividend Growth History: Medtronic has increased its dividend for 48 consecutive years, and while recent hikes have been modest, this track record demonstrates the company's resilience during tough times, with expectations for a return to faster dividend growth in the future.
See More
MiniMed 780G System Receives Health Canada License
- Software Approval: MiniMedGroup, Inc. announced that its MiniMed™ 780G system has received new software licensing from Health Canada, marking a significant advancement in diabetes care that is expected to enhance treatment experiences for Canadian patients.
- Technological Innovation: The new system integrates Meal Detection™ technology and SmartGuard™, compatible with both Guardian™ 4 and Simplera Sync™ sensors, allowing users to manage glucose levels more flexibly, particularly for adults aged 18 and older with Type 2 diabetes.
- Clinical Effectiveness: The MiniMed™ 780G system has demonstrated over 80% time in range in clinical and real-world applications globally, significantly exceeding the international target of 70%, indicating its effectiveness in diabetes management.
- Enhanced User Experience: The introduction of the Simplera Sync™ sensor will reduce daily injection frequency, providing a more comfortable wearing experience, which is expected to further alleviate the daily management burden for patients and strengthen MiniMed's leadership position in the diabetes treatment market.
See More
MiniMed to Report FY 2026 Financial Results on June 3
- Earnings Release Schedule: MiniMed has announced that it will report its fourth quarter and full fiscal year 2026 financial results on June 3, 2026, with a news release expected at 3:45 a.m. PDT, providing summary financial information to help investors gauge the company's performance.
- Webcast Plans: The company will host a webcast at 5:45 a.m. PDT on the same day to discuss the financial results for Q4 and the full year 2026, allowing investors to access detailed insights into the company's financial health and future outlook.
- Replay and Transcript Availability: Within 24 hours of the webcast, MiniMed will make a replay and transcript of the prepared remarks available, enhancing information transparency for investors who could not attend the live session and ensuring they have access to key updates.
- Company Background: MiniMed is a global leader in insulin delivery technology, committed to providing advanced therapies for diabetes management in over 80 countries, highlighting its long-term dedication and innovative capabilities in the diabetes care sector.
See More
Long-Term Investment Opportunities Amid Market Uncertainty
- UPS's Transformation Progress: Despite challenges from Amazon's open delivery network, UPS is shifting towards higher-margin customers, achieving revenue per package growth, and is expected to reach a business inflection point in the second half of 2026, indicating strong long-term investment potential.
- Hormel's Brand Revamp: After a 60% drop in stock price, Hormel Foods is reworking its brand and product portfolio, with recent organic growth trending upward, and its 5.6% dividend yield providing stable returns for long-term investors, showcasing resilience during tough times.
- Medtronic's Focus Strategy: Medtronic is enhancing profitability by spinning off its diabetes business and launching new products like the Hugo surgical robot; despite a 40% stock price decline, its 3.6% dividend yield remains attractive to long-term investors, underscoring its leadership in the medical device sector.
- Importance of Dividends: UPS, Hormel, and Medtronic all offer stable dividends, helping investors maintain confidence during market volatility, and while the market may not fully recognize these companies' business improvements, their long-term outlook remains optimistic.
See More
Long-Term Investment Potential of UPS, Hormel, and Medtronic
- UPS Transformation Progress: Despite competition from Amazon, UPS is shifting towards higher-margin customers and expects to achieve a business turnaround by the second half of 2026, with revenue per package growth indicating management's successful strategy, while a 6.5% dividend yield attracts long-term investors.
- Hormel Brand Restructuring: Hormel Foods is reworking its brand and product portfolio after a 60% stock price decline, with recent organic growth trends improving; its 5.6% dividend yield and 46% controlling stake provide flexibility for long-term decision-making.
- Medtronic Profitability Focus: Medtronic is enhancing profitability by spinning off its diabetes business, which is expected to positively impact earnings; despite a 40% decline from its 2021 high, its 3.6% dividend yield remains appealing to long-term investors.
- Importance of Dividends: UPS, Hormel, and Medtronic offer stable dividends in an uncertain market, helping investors maintain confidence during volatility, while also making significant progress in their business overhauls.
See More
Medtronic Shares Decline, Investors Should Take Note
- Stock Decline: Medtronic (MDT) shares have fallen 40% from their 2021 peak, currently priced at $76.03, reflecting market pessimism about its future performance, prompting investors to assess risks carefully.
- Business Restructuring: The company is readjusting its product portfolio to focus on higher-margin businesses, planning to spin off its lower-margin diabetes division, MiniMed, which is expected to enhance overall profit margins and positively impact earnings.
- New Product Launch: Medtronic is introducing the Hugo surgical robot to fill a market gap, leveraging its strong customer relationships in the healthcare sector, which is anticipated to receive a positive market response and drive future growth.
- Dividend Yield: With a dividend yield of 3.73% and a history of 48 consecutive years of dividend increases, Medtronic, despite recent modest hikes, is positioned for potential faster dividend growth in the future, attracting long-term investor interest.
See More
Medtronic Faces Challenges but Holds Great Potential
- Stock Price Decline: Medtronic's shares have fallen 40% from their 2021 peak, reflecting market concerns over its profitability and growth outlook, although the current dividend yield of 3.6% offers an attractive proposition for investors.
- Portfolio Restructuring: The company is readjusting its product portfolio to focus on higher-margin businesses, planning to spin off its lower-margin diabetes division, MiniMed, which is expected to enhance overall margins and immediately boost earnings.
- New Product Launch: Medtronic is introducing the Hugo surgical robot, which is anticipated to be well-received in the market, especially given its strong customer relationships in the healthcare sector, aiding future growth prospects.
- Dividend Growth History: Medtronic has increased its dividend for 48 consecutive years, and while recent hikes have been modest, this track record demonstrates the company's resilience during tough times, with expectations for a return to faster dividend growth in the future.
See More
MiniMed 780G System Receives Health Canada License
- Software Approval: MiniMedGroup, Inc. announced that its MiniMed™ 780G system has received new software licensing from Health Canada, marking a significant advancement in diabetes care that is expected to enhance treatment experiences for Canadian patients.
- Technological Innovation: The new system integrates Meal Detection™ technology and SmartGuard™, compatible with both Guardian™ 4 and Simplera Sync™ sensors, allowing users to manage glucose levels more flexibly, particularly for adults aged 18 and older with Type 2 diabetes.
- Clinical Effectiveness: The MiniMed™ 780G system has demonstrated over 80% time in range in clinical and real-world applications globally, significantly exceeding the international target of 70%, indicating its effectiveness in diabetes management.
- Enhanced User Experience: The introduction of the Simplera Sync™ sensor will reduce daily injection frequency, providing a more comfortable wearing experience, which is expected to further alleviate the daily management burden for patients and strengthen MiniMed's leadership position in the diabetes treatment market.
See More
MiniMed to Report FY 2026 Financial Results on June 3
- Earnings Release Schedule: MiniMed has announced that it will report its fourth quarter and full fiscal year 2026 financial results on June 3, 2026, with a news release expected at 3:45 a.m. PDT, providing summary financial information to help investors gauge the company's performance.
- Webcast Plans: The company will host a webcast at 5:45 a.m. PDT on the same day to discuss the financial results for Q4 and the full year 2026, allowing investors to access detailed insights into the company's financial health and future outlook.
- Replay and Transcript Availability: Within 24 hours of the webcast, MiniMed will make a replay and transcript of the prepared remarks available, enhancing information transparency for investors who could not attend the live session and ensuring they have access to key updates.
- Company Background: MiniMed is a global leader in insulin delivery technology, committed to providing advanced therapies for diabetes management in over 80 countries, highlighting its long-term dedication and innovative capabilities in the diabetes care sector.
See More
